The Evolution and Impact of Combination Therapies in Treating Stage III and IV Melanoma

By HEOR Staff Writer

October 2, 2023

A New Era in Melanoma Treatment

The landscape of treating stage III and IV malignant melanoma (MM), one of the most aggressive skin cancers, has drastically transformed over the past decade. The introduction of immune checkpoint inhibitors (ICIs) such as ipilimumab (IPI) and nivolumab (NIVO) has revolutionized melanoma treatment, offering increased overall survival rates compared to traditional chemotherapy.

The Rise of Combination Therapies

The development and approval of combination therapies have further enhanced treatment effectiveness. These therapies, which combine two active ingredients in one drug, aim to simplify administration, increase patient adherence, and consequently lower costs. Using a combination of NIVO and IPI as a treatment option, showed improved effectiveness compared to using IPI as monotherapy.

The long-term potential of using combination therapy remains a big topic of debate in the industry. When using fixed combinations there is a limit to adjust individual dose regimens which could potentially reduce efficacy. The safety of combination drugs is also not yet fully understood, and their long-term effects remain to be controversial.

Evaluating Cost-effectiveness

Combination therapies have been proven to be more effective, but they also come with higher costs. Studies have found that NIVO plus IPI is cost-effective in Japan, Canada, and the United States when compared to NIVO, IPI, and pembrolizumab. In Switzerland, however, the combination therapy does not prove to be cost-effective compared to vemurafenib.

The effectiveness of BRAF and MEK inhibitors combination therapy varies. Generally this combination is associated with superiority in terms of progression-free survival, overall survival, and objective response rate compared to monotherapy. This however, will need to be confirmed in terms of the long-term effectiveness and cost-effectiveness of these therapies.

Reference url

Recent Posts

Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for strategic trade at Aspen Pharmacare and c...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health

By João L. Carapinha

October 28, 2025

A BMJ article explores the potential for AI chatbot delusions to validate or induce delusional thinking. Emerging evidence shows that individuals with and without previous psychiatric histories have reported distressing delusions after extensive chatbot interactions. It remains uncertain if AI di...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics

By João L. Carapinha

October 27, 2025

Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...